CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1530
0.00 (0.00%)
At close: Sep 4, 2026
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 214 employees as of December 31, 2025. The number of employees decreased by 19 or -8.15% compared to the previous year.
Employees
214
Change (1Y)
-19
Growth (1Y)
-8.15%
Revenue / Employee
$93,991
Profits / Employee
-$205,449
Market Cap
3.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | -19 | -8.15% | 214 | 0 |
| Dec 31, 2024 | 233 | 57 | 32.39% | 233 | 0 |
| Dec 31, 2023 | 176 | -48 | -21.43% | 176 | 0 |
| Dec 31, 2022 | 224 | 48 | 27.27% | 224 | 0 |
| Dec 31, 2021 | 176 | 32 | 22.22% | 176 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| International Stem Cell | 33 |
| Emmaus Life Sciences | 33 |
| AccuStem Sciences | 4 |
| Bioxytran | 2 |
CASI Pharmaceuticals News
- 21 days ago - CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results - Accesswire
- 6 months ago - CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - Accesswire
- 7 months ago - CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 7 months ago - CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Accesswire
- 8 months ago - CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Accesswire
- 8 months ago - CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Accesswire
- 9 months ago - CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - Accesswire
- 9 months ago - CASI Pharmaceuticals Announces Changes in Board Governance - Accesswire